Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030 WILMINGTON, Del.–(BUSINESS WIRE)–AstraZenecaAppointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030 WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

2026/01/08 20:00
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.

Suarez will lead the execution of the Company’s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca’s largest single manufacturing investment globally.

The investment underpins AstraZeneca’s goal of generating $80 billion in Total Revenue by 2030, with half expected to come from the US, the Company’s largest market.

Suarez said: “We are operating at a moment of unprecedented scientific opportunity. Our responsibility is to translate that science into results for patients and for the US healthcare system. By strengthening our US manufacturing and R&D footprint, we will expand access to innovative medicines, create highly skilled jobs, and deliver long-term value.”

Suarez will have full responsibility for AstraZeneca’s US BioPharmaceuticals organization, with accountability for performance, growth and execution across the portfolio.

Suarez brings more than 20 years of experience in the US healthcare sector, with leadership roles spanning commercial, medical and market access functions at AstraZeneca. He returns to the US after serving as Country President for Spain since 2020, where he led one of AstraZeneca’s strongest performing European markets. He expanded Spain’s role in global clinical development and positioned Barcelona as a strategic hub for innovation.

During his tenure in Spain, Suarez established a new global hub in Barcelona and launched the AstraZeneca Healthcare Innovation Hub, committing more than €10 million to digital health and data-driven initiatives focused on translational innovation.

Suarez will be based at AstraZeneca’s US headquarters in Wilmington, Delaware. His appointment is effective immediately.

Biographical information

Rick Suarez was born in the United States and grew up in New Haven, Connecticut. He joined AstraZeneca in 1999 as a pharmaceutical sales specialist and has worked across many functions of the business including marketing, medical affairs and market access.

Notes

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.

Contacts

Media Inquiries
Fiona Cookson +1 212 814 3923

US Media Mailbox: usmediateam@astrazeneca.com

시장 기회
Talus 로고
Talus 가격(US)
$0.00473
$0.00473$0.00473
-7.25%
USD
Talus (US) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!